Physician profile
Collin Udall
NPI 1861495434
$1,812.90
in general payments reported to CMS, 2019-2025
26 companies · $51.53 in 2025
The $51.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $303 · 2021: $12.72 · 2023: $45.44 · 2025: $51.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $241.70 | 2019-2020 | |
| Pfizer INC. | $223.61 | 2019-2020 | |
| Lilly USA, LLC | $178.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $135.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $116.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $111.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.12 | 2019-2020 | |
| Amarin Pharma, INC. | $74.45 | 2019-2020 | |
| Novo Nordisk INC | $65.98 | 2019-2020 | |
| Abbvie INC. | $59.60 | 2019-2020 | |
| Topcon Healthcare Solutions, INC. | $54.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $52.59 | 2019-2020 | |
| Exact Sciences Corporation | $51.53 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $48.65 | 2019 | |
| Dexcom, INC. | $45.44 | 2023 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $40.47 | 2019-2020 | |
| Boston Scientific Corporation | $31.45 | 2019-2020 | |
| Glaxosmithkline, LLC. | $25.96 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.60 | 2019 | |
| Grifols USA, LLC | $21.28 | 2020 | |
| Abbott Laboratories | $20.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.98 | 2020 | |
| Medtronic Vascular, INC. | $17.41 | 2019 | |
| Medtronic USA, INC. | $13.57 | 2019 | |
| Medtronic, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collin Udall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.